For ovarian cancer susceptible to drug resistance, the intersecting roles of NMT1 and Src signaling indicate that a new therapeutic strategy could involve the combination of NMT1 inhibitors with anticancer drugs [41]. The gene discussed is NMT1; the disease is ovarian cancer.